Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib
The most common type of renal cell carcinoma (RCC) is clear cell renal cell carcinoma (ccRCC), which has a high metastatic potential. Even though the International Metastatic RCC Database Consortium (IMDC) risk model is conventionally utilized for selection and stratification of patients with metas...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2023-01-01
|
Series: | Biomolecules & Biomedicine |
Subjects: | |
Online Access: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/7675 |
_version_ | 1827317511482245120 |
---|---|
author | Marija Kraljević Inga Marijanović Maja Barbarić Emir Sokolović Merima Bukva Timur Cerić Teo Buhovac |
author_facet | Marija Kraljević Inga Marijanović Maja Barbarić Emir Sokolović Merima Bukva Timur Cerić Teo Buhovac |
author_sort | Marija Kraljević |
collection | DOAJ |
description |
The most common type of renal cell carcinoma (RCC) is clear cell renal cell carcinoma (ccRCC), which has a high metastatic potential. Even though the International Metastatic RCC Database Consortium (IMDC) risk model is conventionally utilized for selection and stratification of patients with metastatic RCC (mRCC), there remains an unmet demand for novel prognostic and predictive markers. The goal of this study was to analyze the expression of Vascular endothelial growth factor (VEGF), Cluster of Differentiation 31 (CD31) to determine microvessel density, and Angiopoietin-1 (Ang-1) in primary kidney tumors, as well as their predictive and prognostic value in patients with metastatic ccRCC (mccRCC) who were treated with first-line sunitinib. The study included 35 mccRCC patients who were treated with first-line sunitinib in period between 2009 and 2019. Immunofluorescence was used to examine biomarker expression in tissue specimens of the primary tumor and surrounding normal kidney tissue. Median disease-free survival (DFS) was longer in patients with negative and low tumor VEGF score than in patients with medium tumor VEGF score (p=0.02). Those with low tumor CD31 expression had a longer median DFS than patients with high tumor CD31 expression (p=0.019). There was no correlation between Ang-1 expression and DFS. The expression of biomarkers in normal kidney tissue was significantly lower than in tumor tissue (p<0.001). In conclusion, higher VEGF scores and greater CD31 expression were associated with longer DFS, but neither of these biomarkers correlated with progression-free survival or overall survival.
|
first_indexed | 2024-04-24T23:38:56Z |
format | Article |
id | doaj.art-5c67886500f54f6aa081634be1bb1bd7 |
institution | Directory Open Access Journal |
issn | 2831-0896 2831-090X |
language | English |
last_indexed | 2024-04-24T23:38:56Z |
publishDate | 2023-01-01 |
publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
record_format | Article |
series | Biomolecules & Biomedicine |
spelling | doaj.art-5c67886500f54f6aa081634be1bb1bd72024-03-15T13:30:45ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2023-01-0123110.17305/bjbms.2022.7675Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinibMarija Kraljević0https://orcid.org/0000-0001-8058-9908Inga Marijanović1https://orcid.org/0000-0002-8777-9832Maja Barbarić2https://orcid.org/0000-0001-5874-9047Emir Sokolović3Merima Bukva4Timur Cerić5Teo Buhovac6https://orcid.org/0000-0003-4539-4093Oncology Clinic, University Clinical Hospital Mostar, Mostar, Bosnia and HerzegovinaOncology Clinic, University Clinical Hospital Mostar, Mostar, Bosnia and HerzegovinaLaboratory of Morphology, Department of Histology and Embryology, School of Medicine, University of Mostar, Mostar, Bosnia and HerzegovinaOncology Clinic, Clinical Center University of Sarajevo, Sarajevo, Bosnia and HerzegovinaAssociation of Basic Medical Sciences of FBIH, Sarajevo, Bosnia and HerzegovinaOncology Clinic, Clinical Center University of Sarajevo, Sarajevo, Bosnia and HerzegovinaOncology Clinic, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina The most common type of renal cell carcinoma (RCC) is clear cell renal cell carcinoma (ccRCC), which has a high metastatic potential. Even though the International Metastatic RCC Database Consortium (IMDC) risk model is conventionally utilized for selection and stratification of patients with metastatic RCC (mRCC), there remains an unmet demand for novel prognostic and predictive markers. The goal of this study was to analyze the expression of Vascular endothelial growth factor (VEGF), Cluster of Differentiation 31 (CD31) to determine microvessel density, and Angiopoietin-1 (Ang-1) in primary kidney tumors, as well as their predictive and prognostic value in patients with metastatic ccRCC (mccRCC) who were treated with first-line sunitinib. The study included 35 mccRCC patients who were treated with first-line sunitinib in period between 2009 and 2019. Immunofluorescence was used to examine biomarker expression in tissue specimens of the primary tumor and surrounding normal kidney tissue. Median disease-free survival (DFS) was longer in patients with negative and low tumor VEGF score than in patients with medium tumor VEGF score (p=0.02). Those with low tumor CD31 expression had a longer median DFS than patients with high tumor CD31 expression (p=0.019). There was no correlation between Ang-1 expression and DFS. The expression of biomarkers in normal kidney tissue was significantly lower than in tumor tissue (p<0.001). In conclusion, higher VEGF scores and greater CD31 expression were associated with longer DFS, but neither of these biomarkers correlated with progression-free survival or overall survival. https://www.bjbms.org/ojs/index.php/bjbms/article/view/7675CarcinomaRenal CellSunitinibVEGF-AAng-1PECAM-1 |
spellingShingle | Marija Kraljević Inga Marijanović Maja Barbarić Emir Sokolović Merima Bukva Timur Cerić Teo Buhovac Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib Biomolecules & Biomedicine Carcinoma Renal Cell Sunitinib VEGF-A Ang-1 PECAM-1 |
title | Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib |
title_full | Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib |
title_fullStr | Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib |
title_full_unstemmed | Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib |
title_short | Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib |
title_sort | prognostic and predictive significance of vegf cd31 and ang 1 in patients with metastatic clear cell renal cell carcinoma treated with first line sunitinib |
topic | Carcinoma Renal Cell Sunitinib VEGF-A Ang-1 PECAM-1 |
url | https://www.bjbms.org/ojs/index.php/bjbms/article/view/7675 |
work_keys_str_mv | AT marijakraljevic prognosticandpredictivesignificanceofvegfcd31andang1inpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithfirstlinesunitinib AT ingamarijanovic prognosticandpredictivesignificanceofvegfcd31andang1inpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithfirstlinesunitinib AT majabarbaric prognosticandpredictivesignificanceofvegfcd31andang1inpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithfirstlinesunitinib AT emirsokolovic prognosticandpredictivesignificanceofvegfcd31andang1inpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithfirstlinesunitinib AT merimabukva prognosticandpredictivesignificanceofvegfcd31andang1inpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithfirstlinesunitinib AT timurceric prognosticandpredictivesignificanceofvegfcd31andang1inpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithfirstlinesunitinib AT teobuhovac prognosticandpredictivesignificanceofvegfcd31andang1inpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithfirstlinesunitinib |